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The risk of Alzheimer’s disease is increased for carriers of apoE4 (E4) or the PPAR-a L162V polymorphism (L162V), but it is decreased in fish
and seafood consumers. The link between high fish intake and reduced risk of cognitive decline in the elderly appears not to hold in carriers of E4,
possibly because better cognition is linked to EPA þ DHA in the blood, but only in non-carriers of E4. As yet, no such studies exist in carriers of
L162V. Our objective was to determine whether the plasma fatty acid response to a dietary supplement of EPA þ DHA was altered in carriers of
L162V and/or E4. This was an add-on project; in the original study, men were selected based on whether or not they were carriers of L162V (n 14
per group). E4 status was determined afterwards. All subjects received an EPA þ DHA supplement for 6 weeks. L162V polymorphism did not
interact with the supplement in a way to alter EPA and DHA incorporation into plasma lipids. However, when the groups were separated based on
the presence of E4, baseline EPA and DHA in plasma TAG were 67 and 60 % higher, respectively, in E4 carriers. After the supplementation, there
were significant gene £ diet interactions in which only non-carriers had increased EPA and DHA in plasma NEFA and TAG, respectively.
PPAR-a: ApoE4: EPA: DHA
Alzheimer’s disease (AD) is the commonest form of cognitive
decline in the elderly(1) and there is not yet an effective treat-
ment for AD. Therefore, development of nutritional strategies
such as the consumption of fish and seafood which appear to
be protective against cognitive decline are essential(2 – 5).
Recently, better cognition has been correlated with higher
n-3 fatty acid content in erythrocytes(6), the latter usually
being a direct reflection of n-3 fatty acid intake from fish
and seafood(7,8). Intake of EPA and DHA, the two major n-3
fatty acids composing fish, is well recognised to lower TAG
and increase levels of HDL-cholesterol(9). Some studies have
suggested that EPA and DHA concentrations in the plasma
of those with AD are lower, but, as a whole, the available
literature shows no difference in plasma DHA in those with
AD compared with age-matched controls(3,5). The disconnect
between apparently low DHA intake but normal plasma
DHA in AD possibly results from genetic factors affecting
fatty acid metabolism(3,5).
Two such genetic factors are the L162V polymorphism of
PPAR-a (L162V) and the 14 allele of apoE (E4). Carriers
of either one of these genetic polymorphisms have an altered
plasma lipid profile, thereby possibly enhancing their risk of
cognitive decline(10,11). Indeed, L162V is a potential risk
factor for AD(12) whereas E4 is the most important identified
genetic risk factor for AD(13). Fish and seafood seem not to
protect E4 carriers against AD(14 – 16) and, in contrast to non-
carriers of E4, there was no link in E4 carriers between cog-
nitive performance and total n-3 fatty acids in erythrocytes(15).
To our knowledge, no studies have reported the influence of
the L162V on the link between n-3 fatty acids and cognition
in the elderly.
We hypothesised that the n-3 fatty acid metabolism may be
altered by either one or both the L162V or E4. The objective
of the present study was therefore to assess plasma fatty acid
profile in carriers and non-carriers of the L162V and/or E4
before and after an n-3 fatty acid supplement.
Methods
Subjects and study design
The present study was an add-on project to a previous study
on the impact of L162V on the response of CVD risk factors
to n-3 fatty acid supplementation in men where a complete
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description of the study design is given(17). Twenty-eight
men were selected based on whether they were carriers of
L162V (fourteen carriers; one homozygote, and fourteen
non-carriers). Whether the subjects were also carriers of E4
was only determined after selection for L162V. There were
eight carriers of E4 (one homozygote) and twenty non-carriers
of E4. None of the subjects was homozygous for both L162V
and E4. Subjects consumed 1·9 g EPA and 1·1 g DHA/d for
6 weeks (Ocean Nutrition, Dartmouth, NS, Canada). Capsules
were provided to the subjects in a single bottle with an excess
of capsules blinded to the subjects so as to evaluate compli-
ance to the treatment. No subject was excluded on the basis
of poor compliance.
Fatty acid analysis
Before (baseline, after the run-in phase) and after n-3 fatty
acid supplementation, 12 h overnight fast blood sampling
was done. Plasma was separated by centrifugation and
stored at 2808C until further analysis. Plasma total lipids
were extracted with 2:1 chloroform–methanol and separated
by TLC to obtain phospholipids, TAG, cholesteryl esters
and NEFA. Fatty acids were transmethylated using 14 %
methanolic boron trifluoride, and analysed using GC as pre-
viously described(18).
DNA analysis
Genetic analyses were performed on genomic DNA isolated
from human leucocytes. The L162V polymorphism was deter-
mined as previously described(19). The three commonest
alleles of ApoE (12/13/14) were analysed using the method
described by Hixson & Vernier(20).
Statistics
EPA and DHA data are shown as percentage composition
(relative percentage to other fatty acids) and as the change
(D: after – before the supplement £ 100) in percentage com-
position (mean values and standard deviations). A repeated-
measures ANOVA using a general linear model was applied
to compare means before and after the n-3 supplementation
(SPSS software, version 12.0; SPSS Inc., Chicago, IL, USA)
and a multivariate ANOVA was used to determine gene £ diet
interactions. Baseline or after the n-3 fatty acid supplement
statistical significance between carriers and non-carriers of
E4 was evaluated by independent t tests. Statistical signifi-
cance was defined as P#0·05.
The present study was conducted according to the guide-
lines laid down in the Declaration of Helsinki and all pro-
cedure involving human subjects were approved by the
ethics committees of Universite´ Laval Hospital Research
Centre and Universite´ Laval. Written informed consent was
obtained from all subjects.
Results
Subjects heterozygous or homozygous for either L162V or E4
were grouped together. Based only on L162V, there was no
significant gene £ diet interaction for EPA or DHA in
plasma lipid classes (data not shown). We therefore extended
our analysis to evaluate whether E4 may alter the incorpor-
ation of EPA and DHA in plasma lipids. To assess the
effect of E4 on plasma fatty acids, the subjects were divided
as follows: (i) non-carriers of L162V or E4 (n 11); (ii) non-
carriers of L162V but carriers of E4 (n 3); (iii) carriers of
L162V but non-carriers of E4 (n 9); (iv) carriers of both
L162V and E4 (n 5). There was no significant gene £ diet
interaction for EPA and DHA in plasma lipids (data not
shown). However, the change in EPA and DHA in NEFA or
TAG appeared to be lower in the two groups carrying E4.
We then separated the groups according to the presence of
E4 without regard for L162V. E4 carriers at baseline had
67 % higher EPA and 60 % higher DHA in plasma TAG
(P¼0·018 and P¼0·032 respectively; Fig. 1). There were sig-
nificant gene £ diet interactions for EPA in NEFA and DHA
in TAG (P¼0·043 and P¼0·029, respectively; Fig. 1) since,
in the E4 carriers, the changes (represented by D) were signifi-
cantly lower compared with the non-carriers. The number of
subjects upon which the present study is based appears appro-
priate, since sample-size calculations based on means and
standard deviations of the carriers and non-carriers of E4 for
changes of EPA in NEFA or DHA in TAG and using an a
of 0·05 and a power of 0·8 revealed that six subjects per
group are needed; our two groups were composed of eight
and twenty subjects for the carriers and the non-carriers of
E4 respectively.
Discussion
We report here that after an n-3 fatty acid supplement, incor-
poration of EPA and DHA into plasma NEFA and TAG is
decreased by the presence of E4, but not by L162V. Since
there was no significant gene £ diet interaction when separ-
ated according to the four genotypes, E4 genotype appears
to have a more significant effect on EPA and DHA metab-
olism than L162V.
Most importantly, EPA did not increase in plasma NEFA of
E4 carriers even after consuming the relatively high dose of
1·9 g EPA/d for 6 weeks. Plasma NEFA are reported to be the
preferred fatty acid form for transport into the brain and also
the preferred form to initiate signalling pathways for the syn-
thesis of eicosanoids(21). Our data show that E4 may alter n-3
fatty acid transit into or out of NEFA. E4 also reduced DHA
incorporation into plasma TAG after the supplement, which
indirectly supports the previous suggestion that TAG may be
an important storage or transport pool of DHA(22).
As yet we have no mechanism for this interaction between
E4 and EPA and DHA metabolism, but we will undertake
further studies using the [13C]DHA tracer to determine
whether b-oxidation of DHA is higher in E4 carriers than
non-carriers and whether its incorporation into plasma lipids
is delayed compared with non-carriers. Other possible expla-
nations may relate to the capacity to incorporate and utilise
EPA and DHA upon E4 genotype. Retroconversion of DHA
to EPA may be another possible contributor to explain
higher EPA but since it is apparently very low (about 1·9 %)
in humans, its contribution is unlikely to explain the present
results(23). However, whether the rate of retroconversion of
DHA to EPA is affected in E4 carriers is unknown. Since
the isoforms of ApoE are thought to bind differently to recep-
tors, including the LDL receptor-related protein, thereby
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impacting on lipid transport, especially of TAG and
cholesterol(24), using [13C]DHA could be informative about
how E4 affects n-3 fatty acid metabolism.
Previous studies in E4 carriers and non-carriers reported similar
EPA and DHA in plasma and erythrocyte phospholipids(15,25,26)
and in plasma cholesteryl esters(27), a result that we confirmed
in the present study for plasma phospholipids and cholesteryl
esters since we had no gene £ diet interaction and the increase
was similar to what is reported in the literature(28). However,
contrary to what we anticipated, carriers of E4 had significantly
higher baseline EPA and DHA in plasma TAG (Fig. 1); this is
despite similar EPA and DHA intakes before n-3 fatty acid
supplementation as reported by FFQ and similar baseline
anthropometric and blood biochemistry analysis.
The present study had one major limitation – it was an
add-on to the original project which was not specifically
designed to study variations in the plasma fatty acid response
of E4 carriers and non-carriers to an n-3 fatty acid supplement.
However, based on our calculations, we had sufficient number
of subjects per group to evaluate this gene £ diet interaction.
Since the participants were originally selected based on their
L162V genotype and although we report here no significant
gene £ diet interaction when the groups were separated
based on L162V, we can not exclude the possibility that
L162V interacts with E4. Nevertheless, as previously
suggested(5), these preliminary results give important support
to the idea that E4 affects the link between fish and seafood
intake and possibly the risk for cognitive decline because it
Fig. 1. Average percentage (a–d) and change (D) (e–h) in fasting plasma EPA (a, b, e, f)and DHA (c, d, g, h) in NEFA (a, c, e, g) or TAG (b, d, f, h) of the carriers
( , ) and non-carriers ( , ) of the apoE 14 allele (E4) before and 6 weeks after an n-3 fatty acid supplement. Values are means, with
standard deviations represented by vertical bars. *Mean value was significantly different from that of the non-carriers of E4 at baseline (P #0·05). The gene £ diet
interaction for D EPA in NEFA (e) was significant (P¼0·043); the gene £ diet interaction for D EPA in TAG (f) was NS (P¼0·070); the gene £ diet interaction for
D DHA in NEFA (g) was NS (P¼0·477); the gene £ diet interaction for D DHA in TAG (h) was significant (P¼0·029).
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somehow modulates n-3 fatty acid metabolism. Our data also
suggest that the apparent lack of protection against cognitive
decline by n-3 fatty acids and/or fish and seafood intake in
E4 carriers(14,15) could well involve altered n-3 fatty acid
incorporation into plasma, a possibility that now needs to be
evaluated in an independent well-controlled clinical trial.
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